Baudax Bio, Inc. (OTCPK: BXRX.Q)
Health Care · Pharmaceuticals · US
$0.00
— today · 0.0% 1Y
Baudax Bio, Inc. (OTCPK: BXRX.Q) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $52.00 and employs 9 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores Baudax Bio, Inc. across four factors: quality 6/100, value 37/100. Its strongest factor is value.
BXRX.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $52.00
- Revenue (TTM)
- $1.27M
- P/E
- —
- EPS
- -1.91
- Dividend yield
- —
- Beta (5Y)
- -24.13
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 52.46M
- Employees
- 9
- Next earnings
- —
About Baudax Bio, Inc.
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
- ISIN
- US07160F4046
- Founded
- 2015
- Listed since
- Nov 14, 2019
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,247.37 | -0.64% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.00 | +1.02% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.91 | -1.08% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.03 | -0.14% |
Figures last refreshed Aug 18, 2026.